ai-tools-for-faster-biologic-candidate-selection
The path to a new biologic drug is long and risky, with costly missteps in candidate selection. AI tools now offer a powerful way to de-risk early and accelerate development. Discover how.
Menu
De-Risking Early: How AI Tools Are Shaping Faster Biologic Candidate Selection
FAQ
1. Current Situation
2. Typical Market Trends
3. Current Challenges and How They Are Solved
4. How Leukocare Can Support These Challenges
5. Value Provided to Customers
De-Risking Early: How AI Tools Are Shaping Faster Biologic Candidate Selection
The path to bringing a new biologic drug to market is long and filled with risk. For every success story, countless promising candidates fail somewhere between the lab and the clinic, often for reasons that only become clear late in development. Picking the right lead candidate from the outset is one of the most consequential decisions a drug development team can make. Today, artificial intelligence is offering a new way to look at this old problem, helping teams make smarter, faster decisions.
1. Current Situation
The biologics market is expanding rapidly, with projections suggesting it could hit more than $1 trillion by 2030. This growth is because of the amazing power of therapies like monoclonal antibodies, gene therapies, and viral vectors to treat complex diseases. [1] The process is still slow and expensive. It usually takes 10 to 15 years to develop a new drug, and that can cost billions. [2]
For teams in CMC (Chemistry, Manufacturing, and Controls) and Drug Product (DP) development, the pressure is constant. A virtual biotech with a fast-tracked molecule faces a lot of pressure from the board to get to a Biologics License Application (BLA) quickly. A mid-sized biotech might be working on many projects, needing to grow without adding permanent staff. Everyone needs to move fast, but without cutting corners on quality or regulatory rules. A misstep in candidate selection can lead to costly delays or outright failure years down the line.
2. Typical Market Trends
Two clear trends are shaping the industry. The first trend is the push toward more complex molecules. Teams are no longer just working on standard monoclonal antibodies; they are dealing with new types of treatments like RNA, ADCs, and viral vectors. These molecules bring their own tough stability and manufacturing problems that old methods can't easily fix. [3]
The second trend is the growing use of AI and machine learning into drug discovery. What began with analyzing big data to find targets has now moved firmly into candidate selection and developability. [4] [5] AI is expected to create hundreds of billions of dollars for drug companies by 2025. [6] Companies are using computational tools to predict how a molecule will behave long before it is synthesized in large quantities, aiming to identify and solve problems in silico rather than in the lab. This shift is not about replacing scientists but giving them better tools to deal with more complex molecules and speed things up. [4]
3. Current Challenges and How They Are Solved
The central challenge in early development is uncertainty. Out of dozens of potential candidates, which one has the best chance of becoming a stable, manufacturable, and effective drug? Answering this question used to take months of hard, expensive lab work. Key challenges include:
Predicting Stability: A candidate might show great promise in early assays but later prove too unstable to formulate, store, or administer. This is a main reason things fail later on. [7]
Manufacturability Issues: A molecule may be difficult to produce at scale, leading to low yields or inconsistent quality, putting the whole project at risk.
Limited Resources: Early-stage biotechs, in particular, have limited time, funding, and raw material. They can't afford to thoroughly test dozens of candidates. They have to choose carefully.
The usual way to fix this is called developability assessment. These are early tests that check if a candidate has the right properties to become a drug. These assessments look at factors like aggregation propensity, solubility, and stability under stress to spot possible problems.
Now, AI is making these assessments smarter and faster. [10, 8] Machine learning models can analyze a molecule's sequence and predict its structural stability or likelihood to clump together. Instead of just doing physical tests, teams can screen thousands of digital candidates to pick a few to test in the lab. [11, 12] This computer-based pre-screening helps teams put their efforts on the candidates that have the best chance. [13]
4. How Leukocare Can Support These Challenges
This is precisely where early formulation smarts really make a difference. Rather than seeing formulation as a final step before fill-finish, it should be a strategic tool used from the very beginning to guide how candidates are chosen.
At Leukocare, we use a combination of our Smart Formulation Platform and AI-based stability prediction models to tackle these early problems. Our approach is designed to give CMC and DP leaders the data they need to reduce risks in their projects and move forward confidently.
For the Fast-Track Biotech Leader: You need a smooth, fast path to BLA. The biggest pain is the risk of a surprise later on that throws off tight schedules. We provide early, data-driven formulation insights that help you select a candidate built for regulatory success from day one. Our predictive modeling helps design a formulation in parallel with other CMC activities, making it as stable as possible and ready for the market.
For the Small Biotech with No Internal DP: Your time and resources are limited, and you need partners who can provide structure and clear guidance. We act as an extension of your team, using our platform to create a strong set of data. This makes your CMC story stronger for investors and regulators. It gives them solid, reliable information without you needing to build your own team.
For the Mid-Size Biotech Needing to Break In a New Partner: You have existing workflows but run into problems with new types of treatments or when your teams are too busy. We offer a way to handle a tricky, specific problem, like lyostability or a novel vector, through a pilot project. Our models can provide specific insights to solve a niche challenge, quickly showing our worth and how we can help your DP teams without getting in their way.
Our platform analyzes how a candidate behaves in various formulation conditions, predicting stability to help with candidate selection. This gives teams a clear, evidence-based reason for choosing one candidate over another, based on its potential to be a successful drug.
5. Value Provided to Customers
By bringing together formulation science and predictive analysis at the candidate selection stage, we provide real, clear value to our partners. The goal is to move beyond simply executing experiments and become a strategic partner in the development process.
The core value is risk reduction. By identifying candidates with potential stability or manufacturing problems early on, we help you avoid investing millions of dollars and years of work into a molecule that's going to fail anyway. That means:
Faster Timelines: With a more developable candidate, the path through process development, scale-up, and regulatory filing becomes easier and more predictable.
Efficient Use of Resources: You can focus your lab work, material, and budget on the candidates with the best chance of success.
A Stronger CMC Story: A candidate chosen with formulation and stability data in hand makes a much stronger case for investors and health authorities. It shows you've thought ahead and really understand the whole development process.
Data-Informed Decisions: Instead of relying on limited early data or gut feelings, you gain hands-on support and data that helps you make clear decisions you can stand by.
Choosing the right candidate is about making success more likely. Using advanced predictive tools and early formulation intelligence gives you the information to choose with more confidence.
FAQ
1. How early in the discovery process can we apply predictive formulation tools?
The best time is as soon as you have a few lead candidates after discovery. The earlier we can analyze the molecules, the more impact the data will have on your selection process, saving time and resources before you invest a lot in cell line development and scaling up the process.
2. What kind of data and material do you need to get started?
The process is designed to be material-sparing. We usually start with sequence information for in silico analysis and only need tiny, milligram amounts of a candidate for first lab tests. This gives a good idea of a molecule's stability and formulation needs without using up valuable early-stage material.
3. How does this integrate with our existing discovery and CMC workflows?
Our approach is designed to be a collaborative help, not something that throws things off. We work alongside your discovery and CMC teams, providing formulation and stability data that acts as another key decision point in your existing stage-gate process. We act as a specialized partner, giving specific insights that add to your team's knowledge.
4. Are these predictive tools applicable to new modalities beyond standard antibodies?
Yes. While many models were initially built on antibody data, the ideas behind protein stability and breakdown work for all sorts of treatments. We adapt our platform to handle the special challenges of molecules like viral vectors, antibody-drug conjugates (ADCs), and RNA-based therapeutics, where stability is often a big problem.
